Moonshot Objectives Catalyze New Scientific Breakthroughs—ProteogenomicsRodland, Karin D. PhD; Piehowski, Paul PhD; Smith, Richard D. PhDThe Cancer Journal: May/June 2018 - Volume 24 - Issue 3 - p 121–125 doi: 10.1097/PPO.0000000000000315 Review Articles Buy Abstract Author InformationAuthors Article MetricsMetrics Breaking down the silos between disciplines to accelerate the pace of cancer research is a key paradigm for the Cancer Moonshot. Molecular analyses of cancer biology have tended to segregate between a focus on nucleic acids—DNA, RNA, and their modifications—and a focus on proteins and protein function. Proteogenomics represents a fusion of those two approaches, leveraging the strengths of each to provide a more integrated vision of the flow of information from DNA to RNA to protein and eventually function at the molecular level. Proteogenomic studies have been incorporated into multiple activities associated with the Cancer Moonshot, demonstrating substantial added value. Innovative study designs integrating genomic, transcriptomic, and proteomic data, particularly those using clinically relevant samples and involving clinical trials, are poised to provide new insights regarding cancer risk, progression, and response to therapy. From the Pacific Northwest National Laboratory, Richland, WA. Reprints: Karin D. Rodland, PhD, Battelle for the US DOE Pacific Northwest National Laboratory, PO Box 999, Richland, WA 99352. E-mail: firstname.lastname@example.org. Conflicts of Interest and Sources of Funding: K.D.R., P.P., and R.D.S. are currently receiving National Institutes Health grant funding (5U24 CA210955 and 1U01 CA214116) from the National Cancer Institute—Clinical Proteomic Tumor Analysis Consortium. K.D.R. is also supported by a contract from the National Cancer Institute Early Detection Research Network (IAA IAA no. ACN15006-001), and R.D.S. also receives grant support from NIGMS (5P41 GM103493). Copyright © 2018 Wolters Kluwer Health, Inc. All rights reserved.